Picard Medical Targets 2028 Human Trials for Fully Implantable Artificial Heart
Picard Medical’s Syncardia system has supported more than 2,100 patients with artificial heart pumping support while awaiting transplant. The company is developing a fully implantable next-generation device, targeting human clinical trials in 2028 to replace current external components and expand its market potential.
1. Syncardia System Deployment
Picard Medical’s existing Syncardia system has supported over 2,100 patients with mechanical circulatory support while awaiting transplant, establishing a clinical track record and generating ongoing service and consumables revenue streams.
2. Next-Generation Device Development
The company is advancing a fully implantable artificial heart designed to eliminate external components, with human clinical trials targeted for 2028, aiming to improve patient mobility and reduce infection risks.
3. Market Outlook and Valuation Impact
Successful development of an implantable device could expand Picard’s addressable market beyond bridge-to-transplant applications and strengthen its long-term growth profile, potentially boosting future revenue and valuation.